Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials

被引：39

作者：

Cortes, Jorge E. ^{[1
,7
]}

Dombret, Herve ^{[2
]}

Merchant, Akil ^{[3
]}

Tauchi, Tetsuzo ^{[4
]}

DiRienzo, Christine G. ^{[5
]}

Sleight, Barbara ^{[5
]}

Zhang, Xiaoxi ^{[5
]}

Leip, Eric P. ^{[5
]}

Shaik, Naveed ^{[5
]}

Bell, Timothy ^{[5
]}

Chan, Geoffrey ^{[5
]}

Sekeres, Mikkael A. ^{[6
]}

机构：

[1] Augusta Univ, Georgia Canc Ctr, Augusta, GA 30912 USA

[2] Hop St Louis, Inst Univ Hematol, AP HP, Inst Rech St Louis, Paris, France

[3] Univ Southern Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA

[4] Shin Yurigaoka Gen Hosp, Dept Hematol, Kawasaki, Kanagawa, Japan

[5] Pfizer Inc, Pfizer Oncol, New York, NY 10017 USA

[6] Cleveland Clin, Leukemia Program, Cleveland, OH 44195 USA

[7] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77054 USA

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 31期

关键词：

acute myeloid leukemia; glasdegib; Hedgehog signaling pathway; intensive chemotherapy; myelodysplastic syndrome; nonintensive chemotherapy; smoothened inhibitor; HEDGEHOG PATHWAY; OLDER PATIENTS; INHIBITOR; PF-04449913; AZACITIDINE; RECOMMENDATIONS; CLASSIFICATION; MALIGNANCIES; COMBINATION; SURVIVAL;

D O I：

10.2217/fon-2019-0373

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Glasdegib, an oral Hedgehog pathway inhibitor, has been associated with significantly improved survival when combined with low-dose cytarabine in patients with untreated acute myeloid leukemia (AML) who were unsuitable for intensive chemotherapy, when compared with low-dose cytarabine alone. BRIGHT AML 1019 (NCT03416179) comprises two independently powered Phase III, randomized (1:1), double-blind global trials evaluating oral glasdegib 100 mg once daily or placebo plus one of two standard chemotherapy regimens in adults with untreated AML. The intensive trial combines glasdegib/placebo with cytarabine and daunorubicin (7 + 3), while the nonintensive trial combines glasdegib/placebo with azacitidine. The primary end point of both studies is overall survival. Secondary end points include response, time to and duration of response, event-free survival, safety, patient-reported outcomes and pharmacokinetics.

引用

页码：3531 / 3545

页数：15

共 45 条

[1] Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling
Aberger, Fritz
Hutterer, Evelyn
Sternberg, Christina
del Burgo, Pedro J.
Hartmann, Tanja N.
[J]. CELL COMMUNICATION AND SIGNALING, 2017, 15
[2] [Anonymous], 2019, Cancer Facts and Figures
[3] [Anonymous], 2017, J CANC SCI THER
[4] [Anonymous], BIOL BLOOD MARROW TR
[5] [Anonymous], INDUCTION THERAPY AC
[6] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Arber, Daniel A.
Orazi, Attilio
Hasserjian, Robert
Thiele, Jurgen
Borowitz, Michael J.
Le Beau, Michelle M.
Bloomfield, Clara D.
Cazzola, Mario
Vardiman, James W.
[J]. BLOOD, 2016, 127 (20) : 2391 - 2405
[7] Borate U, 2016, HAEMATOLOGICA, V101, P73
[8] A CONFIDENCE-INTERVAL FOR THE MEDIAN SURVIVAL-TIME
BROOKMEYER, R
CROWLEY, J
[J]. BIOMETRICS, 1982, 38 (01) : 29 - 41
[9] GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML
Chaudhry, Parvesh
Singh, Mohan
Triche, Timothy J.
Guzman, Monica
Merchant, Akil A.
[J]. BLOOD, 2017, 129 (26) : 3465 - 3475
[10] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Cortes, Jorge E.
Heidel, Florian H.
Hellmann, Andrzej
Fiedler, Walter
Smith, B. Douglas
Robak, Tadeusz
Montesinos, Pau
Pollyea, Daniel A.
DesJardins, Pierre
Ottmann, Oliver
Ma, Weidong Wendy
Shaik, M. Naveed
Laird, A. Douglas
Zeremski, Mirjana
O'Connell, Ashleigh
Chan, Geoffrey
Heuser, Michael
[J]. LEUKEMIA, 2019, 33 (02) : 379 - 389

← 1 2 3 4 5 →